Atlas Trials

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Clinical trial NCT03110484 · UNKNOWN

Trial details

NCT number
NCT03110484
Sponsor
Samsung Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2021-07-09
Primary completion
2023-06-14
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.